Nov 16, 2025
3 min read
Recent studies have shown that Ozempic and Momendaro have significant cardiovascular potential in terms of weight loss and blood sugar control.Real-life studies f
Ozempic and Mounjaro, two of the most widely used diabetes and weight loss drugs in the world, may be doing much more than helping people control blood sugar and lose weight.A new study has been published.
Natural medicine shows that these drugs are also associated with a significant reduction in the risk of major cardiovascular events such as stroke and heart failure.The findings come from researchers at the Technical University of Munich (TUM) and Harvard Medical School, who analyzed real health records to understand how these treatments are applied in everyday healthcare.
The benefits of Ozempic and Muvanjaro go beyond weight loss
Although Ozempic and Mounjaro are known for their impressive weight loss effects, studies have shown that their heart benefits cannot be explained by weight changes alone.According to lead author Dr.Nils Kruger, the protective effects appear early and appear to involve direct changes in the body's cardiovascular system.Exactly how this happens is still being researched.
What Your Cholesterol Report Hides - The Truth That Could Save Your Heart |Dr. Vinayak Aggarwal
This is important because people with type 2 diabetes face a higher risk of heart disease than the general population.Treatment can be a big step forward in blood sugar management, weight loss, and reducing the risk of heart attack or stroke.
Real-world data show strong cardiovascular protection
Unlike clinical trials, which involve highly selected volunteers, this study used insurance data from thousands of people living with type 2 diabetes.
These are real patients of different ages, health conditions and lifestyle factors.By studying them, the team was able to see how semaglutide (Ozempic) and tirzepatide (Mounjaro) really work in everyday medical practice.
The results were encouraging.Semaglutide reduced the combined risk of stroke and heart attack by about 18 percent compared with sitagliptin, a diabetes drug that does not protect the heart.Terzepatide showed a 13 percent reduction in a broad measure that included heart attack, stroke and death, compared with dulaglutide, an older GLP-1 medication.
Ozempic short mounjaro
There is a lot of talk about which medicine is better.Pharmacies claim that their products offer stronger protection, but this study finds little difference between the two.In other words, both are effective for heart health.
It is necessary to convince the doctors, starting with Professor Imandan Zinkert Hermant.These drugs seem to benefit the heart by altering blood sugar and blood sugar.
A possible turning point in the treatment of diabetes
Medicines based on GLP-1 are already changing the way diabetes and obesity are treated.Now, with evidence of heart protection as well, these drugs may become key tools in the prevention of cardiovascular disease, which remains one of the biggest threats to health worldwide.
More research and direct comparisons in clinical trials are still needed.But for now, the message from this real-world study is clear.Ozempic and Mounjaro not only help people lose weight and control diabetes.They may also protect the heart in ways that doctors are just beginning to fully understand.
Please note: The information in this article is for educational purposes only and is not intended as medical advice.Always consult a qualified health care professional before starting any new medication or treatment and before changing your diet or supplement regimen.
